Chimeric anti-CD20 monoclonal antibody that depletes B cells via complement-dependent cytotoxicity, antibody-dependent cellular cytotoxicity, and direct apoptosis.
Chimeric anti-CD20 monoclonal antibody that binds CD20 on B cells and depletes CD20+ cells via complement-dependent cytotoxicity (CDC), antibody-dependent cellular cytotoxicity (ADCC), and direct induction of apoptosis.
YES
DIRECT
Rituximab binds CD20 on B cells and triggers killing via complement-dependent cytotoxicity, antibody-dependent cellular cytotoxicity (through FcγR-expressing effector cells), and direct induction of apoptosis upon CD20 crosslinking.
Anti-CCR8 monoclonal antibody that depletes CCR8+ tumor-infiltrating regulatory T cells via ADCC to reprogram the tumor microenvironment.
Anti-CCR8 monoclonal antibody that binds CCR8 on tumor-infiltrating regulatory T cells, blocks CCL1–CCR8 signaling, and induces Fc-mediated ADCC to deplete CCR8+ Tregs, reducing immunosuppression and enhancing antitumor immunity.
YES
DIRECT
Antibody binds CCR8 on Tregs and engages Fcγ receptors on NK cells/macrophages to mediate ADCC, depleting CCR8+ cells.
IgG1 monoclonal antibody targeting CD38; induces ADCC, CDC, and direct apoptosis of myeloma cells.
Humanized IgG1 monoclonal antibody against CD38 that binds CD38 on myeloma cells and induces antibody-dependent cellular cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC), and direct apoptotic signaling, leading to lysis of CD38-expressing tumor cells.
YES
DIRECT
Isatuximab binds CD38 on target cells and induces killing via ADCC (NK cell–mediated), CDC (complement), and direct pro-apoptotic signaling, leading to lysis of CD38-expressing cells.
Autologous, gene-modified T cells engineered to express a CAR targeting CD19 on malignant B cells, inducing T-cell activation and cytotoxic killing of tumor cells.
Autologous T cells are genetically engineered to express a chimeric antigen receptor that binds CD19 on B cells; upon antigen engagement, CAR signaling (CD3ζ with costimulatory domains such as CD28 or 4‑1BB) activates the T cells to proliferate, secrete cytokines, and mediate cytotoxic killing of CD19‑positive malignant B cells.
YES
DIRECT
CAR T cells recognize CD19 and directly kill CD19+ cells via T-cell cytotoxicity (perforin/granzyme release and Fas–FasL–mediated apoptosis).
Humanized IgG1 monoclonal antibody targeting TIGIT to block TIGIT–CD155 signaling and enhance anti-tumor immunity; Fcγ-engaging checkpoint inhibitor.
Humanized IgG1 monoclonal antibody against TIGIT that blocks TIGIT–CD155 (and CD112) interactions, relieving inhibitory signaling on T and NK cells to restore anti-tumor activity; the Fcγ-engaging IgG1 can recruit effector functions (e.g., ADCC/ADCP) against TIGIT-expressing cells.
YES
DIRECT
Anti-TIGIT IgG1 binds TIGIT on cells and engages Fcγ receptors on NK cells/macrophages to mediate ADCC/ADCP (and potentially CDC), depleting TIGIT-expressing cells.